Mesoblast's Ryoncil® Revenues Surge 60% as Financing and Label Expansion Plans Advance — Mesoblast Limited

Event summary

Ryoncil® net revenues increased to US$30M for the quarter ended December 31, 2025, a 60% rise from the prior quarter.
Mesoblast secured a US$125M non-dilutive credit line at 8.00% interest, reducing financing costs and extending repayment terms.
Early real-world data shows 84% survival rate for 25 pediatric patients treated with Ryoncil®, aligning with prior clinical results.
FDA provided positive feedback on potential Biologics License Application (BLA) for rexlemestrocel-L in chronic discogenic low back pain (CLBP).
Pivotal trial for Ryoncil® in adult SR-aGvHD patients expected to commence site enrollment this quarter.

The big picture

Mesoblast's strong quarterly performance underscores its leadership in allogeneic cellular medicines, particularly in the niche of inflammatory diseases. The company's ability to secure non-dilutive financing at favorable terms positions it well for expansion, while positive FDA feedback on rexlemestrocel-L suggests potential for diversification beyond Ryoncil®. The strategic focus on label expansion and real-world clinical outcomes highlights Mesoblast's commitment to addressing unmet medical needs in both pediatric and adult populations.

What we're watching

Label Expansion: Whether Mesoblast can successfully expand Ryoncil® into the adult SR-aGvHD market, a population three times larger than the pediatric segment.
Regulatory Progress: The pace at which rexlemestrocel-L advances through the FDA process, particularly given the positive feedback on the BLA filing.
Financial Flexibility: How Mesoblast utilizes the new US$125M credit line to fund strategic partnerships and label expansion initiatives without diluting shareholders.